Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin

Annals of Vascular Surgery

Volumn 27, Issue 3, 2013, Pages 355-369

  Yoshida, Ricardo De Alvarenga ^a   Yoshida, Winston Bonetti ^a   Maffei, Francisco Humberto De Abreu ^a   El Dib, Regina ^a   Nunes, Rogério ^a   Rollo, Hamilton Almeida ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; APIXABAN; BEMIPARIN; DABIGATRAN; ENOXAPARIN; FONDAPARINUX; RIVAROXABAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BIBLIOGRAPHIC DATABASE; BLEEDING; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTRONIC MEDICAL RECORD; EMBASE; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MEDLINE; META ANALYSIS; MORTALITY; ORTHOPEDIC SURGERY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SURGICAL RISK; SYMPTOM; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; CLINICAL TRIALS, PHASE III AS TOPIC; ENOXAPARIN; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; MIDDLE AGED; ODDS RATIO; ORTHOPEDIC PROCEDURES; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SURGICAL PROCEDURES, ELECTIVE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84875228265     PISSN: 08905096     EISSN: 16155947     Source Type: Journal    
DOI: 10.1016/j.avsg.2012.06.010     Document Type: Review

References (44)

1. T. Fuji, T. Ochi, S. Niwa, and S. Fujita Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin J Orthop Sci 13 2008 442 451
2. W.H. Geerts, D. Bergqvist, and G.F. Pineo Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th ed Chest 133 2008 381S 453
3. S. Haas New anticoagulants - towards the development of an "ideal" anticoagulant Vasa 38 2009 13 29
4. R.A. Yoshida, W.B. Yoshida, and H.A. Rollo New anticoagulants for the prophylaxis of venous thromboembolism J Vasc Bras 10 2011 145 153
5. W.B. Yoshida, R.P. El Dib, R.d.e. A. Yoshida, and F.H. Maffei Ximelagatran versus warfarin for prophylaxis of venous thromboembolism in major orthopedic surgery: systematic review of randomized controlled trials Sao Paulo Med J 124 2006 355 361
6. D. Garcia, E. Libby, and M.A. Crowther The new oral anticoagulants Blood 115 2010 15 20
7. A.G. Turpie, K.A. Bauer, B.I. Eriksson, and M.R. Lassen Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies Arch Intern Med 162 2002 1833 1840
8. S.E. Wolowacz, N.S. Roskell, J.M. Plumb, J.A. Caprini, and B.I. Eriksson Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis Thromb Haemost 101 2009 77 85
9. M.V. Huisman, D.J. Quinlan, O.E. Dahl, and S. Schulman Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials Circ Cardiovasc Qual Outcomes 3 2010 652 660
10. M. Ufer Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development Thromb Haemost 103 2010 572 585
11. J. Huang, Y. Cao, C. Liao, L. Wu, and F. Gao Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials Thromb Haemost 105 2011 245 253
12. A.G.G. Turpie, G. Agnelli, and W. Fisher Benefit-to-risk profile of the ultra-molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE): a meta-analysis Pathophysiol Haemost Thromb 37 2010 OC332
13. Y.B. Cao, J.D. Zhang, H. Shen, and Y.Y. Jiang Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials Eur J Clin Pharmacol 66 2010 1099 1108
14. S. Turun, L. Banghua, Y. Yuan, L. Zhenhui, N. Ying, and C. Jin A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement Thromb Res 127 2011 525 534
15. J.P. Higgins, S.G. Thompson, and D.J. Spiegelhalter A re-evaluation of random-effects meta-analysis J R Stat Soc Ser A Stat Soc 172 2009 137 159
16. P. Juni, A. Witschi, R. Bloch, and M. Egger The hazards of scoring the quality of clinical trials for meta-analysis JAMA 282 1999 1054 1060
17. T. Fuji, C.J. Wang, and S. Fujita Edoxaban versus enoxaparin for thromboprophylaxis after knee arthroplasty: the Stars E-3 trial Pathophysiol Haemost Thromb 37 2010 OC297
18. S. Fujita, T. Fuji, M. Nakamura, and Y. Kawai Safety and efficacy of edoxaban in patients undergoing hip fracture surgery Pathophysiol Haemost Thromb 3 2010 A95 P366
19. K.A. Bauer, B.I. Eriksson, M.R. Lassen, and A.G. Turpie Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery N Engl J Med 345 2001 1305 1310
20. B.I. Eriksson, K.A. Bauer, M.R. Lassen, and A.G. Turpie Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery N Engl J Med 345 2001 1298 1304
21. M.R. Lassen, K.A. Bauer, B.I. Eriksson, and A.G. Turpie Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison Lancet 359 2002 1715 1720
22. A.G. Turpie, K.A. Bauer, B.I. Eriksson, and M.R. Lassen Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial Lancet 359 2002 1721 1726
23. B.I. Eriksson, L.C. Borris, and R.J. Friedman Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775
24. A.K. Kakkar, B. Brenner, and O.E. Dahl Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 31 39
25. M.R. Lassen, W. Ageno, and L.C. Borris Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786
26. A.G. Turpie, M.R. Lassen, and B.L. Davidson Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 2009 1673 1680
27. B.I. Eriksson, O.E. Dahl, and N. Rosencher Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185
28. B.I. Eriksson, O.E. Dahl, and N. Rosencher Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956
29. J.S. Ginsberg, B.L. Davidson, and P.C. Comp Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 2009 1 9
30. B.I. Eriksson, O.E. Dahl, and M.H. Huo Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial Thromb Haemost 105 2011 721 729
31. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and R.J. Portman Apixaban or enoxaparin for thromboprophylaxis after knee replacement N Engl J Med 361 2009 594 604
32. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 2010 807 815
33. M.R. Lassen, A. Gallus, G.E. Raskob, G. Pineo, D. Chen, and L.M. Ramirez Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N Engl J Med 363 2010 2487 2498
34. A. Navarro-Quilis, E. Castellet, E. Rocha, J. Paz-Jimenez, and A. Planes Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial J Thromb Haemost 1 2003 425 432
35. M.V. Huisman, D.J. Quinlan, O.E. Dahl, and S. Schulman Enoxaparin vs. dabigatran etexilate or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty [abstract] J Thromb Haemost 7 Suppl 2 2009 Abstract PP-TH-413
36. B.I. Eriksson, D.J. Quinlan, and J.W. Eikelboom Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism Annu Rev Med 62 2011 41 57
37. A.G. Turpie, M.R. Lassen, and B.I. Eriksson Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies Thromb Haemost 105 2011 444 453
38. R.J. Friedman, O.E. Dahl, and N. Rosencher Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials Thromb Res 126 2010 175 182
39. R.D. Hull, J. Liang, and R. Brant Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled Thromb Res 126 2010 164 165
40. G. Merli, A.C. Spyropoulos, and J.A. Caprini Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations Ann Surg 250 2009 219 228
41. R.D. Hull, R.D. Yusen, and D. Bergqvist State-of-the-art review: assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis Clin Appl Thromb Hemost 15 2009 377 388
42. D. Van Thiel, E. Kalodiki, R. Wahi, E. Litinas, W. Haque, and G. Rao Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery Clin Appl Thromb Hemost 15 2009 389 394
43. D. Welzel, R. Hull, and J. Fareed Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux Int Angiol 30 2011 199 211
44. O.E. Dahl, D.J. Quinlan, D. Bergqvist, and J.W. Eikelboom A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty J Thromb Haemost 8 2010 1966 1975